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Background: Schizophrenia is a significantly disabling disease that affects all major areas of life. There is a lack of
comprehensive synthesis of research findings on the full extent of psychosocial difficulties (PSDs) experienced by
people living with schizophrenia. This paper provides a systematic review of the literature concerning PSDs and
their associated factors in schizophrenia. PSDs were conceptualized in accordance with the International
Classification of Functioning, Disability and Health (ICF) as disabilities, in particular impairments of mental functions,
activity limitations and participation restrictions.
Methods: An electronic search using MEDLINE and PsychINFO plus a manual search of the literature was
performed for qualitative and longitudinal studies published in English between 2005 and 2010 that examined
PSDs in persons with schizophrenia. The ICF was used as a conceptual framework.
Results: A total of 104 papers were included. The most frequent PSDs addressed in the literature were not specific
ones, directly linkable to the ICF categories of mental functions, activity limitations or participation restrictions, but
broad areas of psychosocial functioning, such as psychopathological symptoms (53% of papers) or global disability
and functioning (37%). Among mental functions, the most extensively studied were cognitive functions (27%) and
emotional functions (27%). Within the domain of activities and participation, the most widely investigated were
difficulties in relationships with others (31%) and employment (20%). Of the factors associated with the intensity or
course of PSDs, the most commonly identified were treatment modalities (56%), psychopathological symptoms
(26%), and socio-demographic variables (24%). Medication tended to improve the most relevant PSD, but at the
same time was the only consistently reported determinant of onset of PSDs (emerging as unwanted side-effects).
Conclusions: The present review illustrates the remarkably broad scope and diversity of psychosocial areas affected
in schizophrenia and shows how these areas are interconnected and how they interact with contextual factors. The
need for a shift in focus of schizophrenia research is suggested – from an excessive reliance on global measures of
psychopathology and disability for defining outcomes to the creation of profiles of specific PSDs that have a more
direct bearing on the disabling experience and real-world functioning of patients and can serve to guide
interventions and monitoring over time.
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Schizophrenia is a severe psychotic disorder character-
ized by a chronic and relapsing course with generally in-
complete remissions, substantial functional decline,
frequent psychiatric and medical co-morbidities and
increased mortality [1]. Although several long-term fol-
low-up studies have undermined the original view about
its inevitably poor outcome and proved that varying
degrees of recovery are possible [2], schizophrenia is still
ranked among the top ten leading causes of disease-
related disability in the world [3] and is consistently
demonstrated to have a major negative impact on quality
of life [4].
Given the magnitude and pervasiveness of the impair-
ments associated with schizophrenia [1], only limited ef-
fectiveness of existing treatments [5], and the prevalence
of stigma [6], people with schizophrenia commonly ex-
perience a wide and diverse array of psychosocial diffi-
culties reaching far beyond the symptoms of the disease.
Previous literature reviews analyzed various aspects of
psychosocial disability in schizophrenia, such as psycho-
pathological symptoms [7,8], or impairments of basic
cognition [9], social cognition [10], emotional experience
[11], social functioning [12], vocational functioning [13]
and quality of life [14], but failed to systematically
synthesize the data across the entire breadth of psycho-
social problems experienced by people with this disease.
Therefore, since the existing literature does not ad-
equately reflect the overall experience and burden of liv-
ing with schizophrenia, a review is needed to provide a
comprehensive perspective on the totality of psycho-
social difficulties associated with schizophrenia in order
to allow for better intervention targeting and to suggest
guidance for future research.
One of the main reasons the data on the entire range
of schizophrenia-related psychosocial problems has not
been satisfactorily summarized is the lack of consensus
how to define psychosocial outcomes [15]. In the present
review, we propose to define psychosocial difficulties
(PSDs) according to the biopsychosocial approach found
in the World Health Organization’s International Classi-
fication of Functioning, Disability and Health (ICF) [16].
The ICF provides a universal, common language for the
description of health and health-related states, resulting
from an interaction between the underlying health condi-
tion and contextual factors, namely environmental and
personal factors. In other words, we do not regard PSDs
to be direct consequences of schizophrenia, but mediated
by the environment in which people with schizophrenia
live. In accordance with the ICF framework, PSDs asso-
ciated with schizophrenia can therefore be characterized
as impairments of mental functions (such as emotional
functions) and activity limitations and participation
restrictions in such domains as work, family life andleisure activities. Environmental factors such as stigma, a
supportive family as well as personal factors, such as con-
fidence in one’s ability to overcome difficulties, can have
a positive or negative impact on PSDs. Because PSDs are
often analyzed by researchers in the context of several
broader concepts, such as disability, functioning, quality
of life, wellbeing or health status, we decided to include
these notions in the analysis, even though we do not con-
sider them to be specific PSDs. Also pain and sexual
interest problems, which belong to the body functions
component of the ICF but are not mental functions, were
included due to their substantial psychological compo-
nent and great importance in neuropsychiatric disorders.
Our review was performed within the scope of the EU
funded project “Psychosocial fActors Relevant to brAin
DISorders in Europe (PARADISE)” (http://paradiseproject.
eu/), a project which aims to develop and test an innova-
tive approach to collecting clinical data on PSDs that
people with brain disorders experience in daily life. The
key to this approach is the hypothesis that people with
very distinct brain conditions – including dementia, de-
pression, epilepsy, migraine, multiple sclerosis, Parkinson's
disease, schizophrenia, stroke and substance use disorders
– share common PSDs because, once again, these difficul-
ties are not direct consequences of the health condition
alone but are outcomes of the interaction between the
health condition and contextual factors.
To provide a comprehensive overview of the most
common PSDs in schizophrenia we reviewed qualitative
and longitudinal studies targeting onset, intensity and
course of PSDs experienced by adults with a diagnosis of
schizophrenia. The specific objectives of the present sys-
tematic review were:
a) to acquire a comprehensive overview of the most
common PSDs in schizophrenia;
b) to identify the most common factors associated with
their onset, intensity and course; and
c) to identify gaps and weaknesses in the literature.
Methods
Search strategy
Electronic databases (MEDLINE and PsychINFO) were
searched for studies published in English between Janu-
ary 2005 and May 2010 that examined psychosocial diffi-
culties, as defined above, in persons with schizophrenia.
Search terms were customized to each database by com-
bining the terms schizophrenia and schizophren* with
the following key words: psychosocial*, Quality of Life/,
Personal Satisfaction/, exp Human Activities/ and exp
Social Support/ disabilit*, homelessness, environmental
factor*, exp Interpersonal Relations/, Quality of Life/,
Personal Satisfaction/, exp Human Activities/, paternal-
ism/, prejudice/, psychosocial deprivation/, social values/
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tion/, stereotyping/, exp Social Environment/, exp emo-
tions/, exp family/, exp socioeconomic factors/, exp life
style/, exp Disability evaluation/, Communication Bar-
riers/, Adaptation, Psychological/, Aggression/, Psycho-
logical stress/, (community not microbial community),
or (sexual* or intimacy). The specific search strategies
used in Medline and PsychINFO are presented in Add-
itional file 1. Furthermore, reference lists of important
systematic reviews targeting psychosocial difficulties in
schizophrenia were screened for other relevant studies.Inclusion and exclusion criteria
With respect to the study population, papers were
regarded as eligible for inclusion in the review if they fo-
cused on the perspective of adults with a diagnosis of
schizophrenia. Studies performed on samples comprising
patients with other psychotic disorders (e.g. schizotypal
disorders, persistent delusional disorders, acute and
transient psychotic disorders, induced psychotic disor-
ders, or schizoaffective disorders) were excluded, unless
the data concerning schizophrenia patients were ana-
lyzed and reported separately. Regarding study design,
randomized controlled trials, clinical controlled trials,
longitudinal observational studies, qualitative studies,
case–control studies, economic evaluations, and study
protocols were included. Excluded were primary preven-
tion studies, phase I and II studies, ecologic studies,
cross-sectional studies, systematic reviews, case reports/
case series and psychometric studies. As far as publica-
tion type is concerned, only original research reports
published as journal articles were considered for ana-
lysis, whereas book chapters, dissertations, guidelines,
commentaries, letters to the editor, editorials, and con-
ference reports were not eligible. Additional general ex-
clusion criteria were as follows: absence of psychosocial
factors analyzed as dependent variables, exclusive focus
on caregiver’s burden, risk factors leading to schizophre-
nia, or environmental factors not considering the impact
of those factors in persons with schizophrenia.Data extraction and analysis
All retrieved abstracts were screened for relevance by a
trained reviewer. In order to enhance quality and reli-
ability of this process, 20% of abstracts were randomly
selected for a second check by another reviewer (blinded
to the decision made by the other). Disagreements were
resolved by consensus. Subsequently, full texts of papers
rated as eligible were retrieved and analyzed in detail by
one reviewer. 10% of full articles were double checked
independently by two reviewers. The reviewers were psy-
chiatrists with considerable experience in mental health
research and practice (PŚ, ACh, MA).Information from each study relevant to the research
aims and which satisfied inclusion criteria was extracted.
The extracted data referred to the study characteristics
and to the PSDs reported. Information about study char-
acteristics that was extracted was: the objective of the
study, its design, intervention, if any, size and characteris-
tics of the study population, outcome variables included,
instruments used to assess them and research findings.
The information extracted regarding PSDs was: the as-
sessment method or instrument used, description of fea-
tures of the PSD, such as onset (when the PSD began),
intensity and nature of change over time (improvement,
no change or worsening), and the factors related to PSDs.
Variables were considered to be associated with PSDs if
they showed statistically significant associations with the
above mentioned features of PSDs in quantitative studies
or were identified as such by the respondents in qualita-
tive studies. Because in this study we were only interested
in PSDs treated as dependent variables, we did not in-
clude here variables predicted by PSDs or which were
analyzed in the papers as consequences of PSDs.
In the next step, the extracted PSDs were grouped into
conceptually or thematically-related categories based on
the ICF using the linking rules described by Cieza et al.
[17]. The ICF standardized categories of PSDs were then
grouped by similarity of content into overarching cat-
egories following guidelines for narrative synthesis
described by Popay et al. [18]. A similar thematic
categorization was performed also for the factors related
to PSDs. In order to reduce the complexity of the data
and the number of analyses needed, the factors asso-
ciated with intensity and course of PSDs were analyzed
jointly. A separate analysis was conducted for the factors
associated with onset of PSDs. The importance of PSDs
and associated factors was then assessed by calculating
the number of studies in which they were identified.
Only PSDs and associated variables which appeared in at
least 5 papers were reported here. Subsequently, the
types of relationships with associated variables were ana-
lyzed in detail for the 10 most frequent PSDs.
Finally, the quality of the studies was rated by investi-
gators on a four-point scale (1-poor, 2-acceptable, 3-
good, 4-excellent). The quality assessment was per-
formed on the basis of the National Institute for Health
and Clinical Excellence (NICE) guidelines [19]. Only
papers of at least acceptable quality were retained for
the final analysis.Results
Determining relevant literature
Study selection process is presented in Figure 1. A total
of 104 papers formed part of the review (see Additional
file 2 for the full list of the included papers).
Full-text articles assessed for 
eligibility (n=469)
Papers meeting inclusion 
criteria (n=93)
Additional papers identified 
by searching reference lists 
of previously published 
systematic reviews (n=17) 
Papers included in the review 
(n=104)    
Records excluded after abstract check due to 
lack of PSDs consistent with the adopted 
definition, irrelevant study design, diagnosis 
poorly defined, irrelevant study population, 
focus on caregiver’s burden, irrelevant 
publication type (n=1010)
Papers excluded after full-text check due to 
irrelevant study design, irrelevant study 
population, lack of PSDs consistent with the 
adopted definition, diagnosis poorly defined
(n=376)
Papers excluded due to poor quality (n=6)
Records after duplicates 
removed (n=1479)
Records identified through 
electronic database search 
(n=1779)
Figure 1 Flow diagram of paper selection process.
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The overall quality of the included studies was rather
high: 13 (12.5%) were rated as excellent, 72 (69.2%) were
judged to be good, and 19 (18.3%) were assessed as ac-
ceptable. Seventeen (16.3%) studies were cross-national.
Among the single country studies (n = 87, 83.7%), the
most frequently represented countries were the USA (n
= 18), Germany (n = 12), Spain (n = 9), and Israel (n =
7). The overwhelming majority of the studies (n = 94,
90.4%) were quantitative in nature, while only nine
(8.7%) were qualitative, and one (1%) used a mixed-
method design with both quantitative and qualitative
data collected. The quantitative studies (including a
quantitative part of the mixed-method study) were al-
most evenly split between interventional (n = 48) and
observational studies (n = 47).The study sample sizes varied from 4 to 9340 (median
= 92) with a proportion of women ranging from 0% to
100% (median = 38.5%). Mean age of the participants
was between 23.0 and 69.5 years. Only 25 (24%) studies
reported mean time since illness onset for the sample
which fell between 0.6 and 26.9 years. Additional file 3:
Table S1 presents characteristics and a brief summary of
findings of each study included in the review.
Psychosocial difficulties (PSDs)
A total of 678 study outcomes related to PSDs were
identified in the literature which were classified under
115 categories. The most relevant PSDs associated with
schizophrenia are displayed in Table 1. a
The most extensively studied were not concrete, spe-
cific PSDs, but global scores and global concepts closely
Table 1 Frequency of psychosocial difficulties (PSDs)
associated with schizophrenia identified in the literaturea




Cognitive functions 28 (26.9)
in general (b1) 14 (13.5)
attention (b140) 11 (10.6)
memory (b144) 8 (7.7)
thought functions (b160) 8 (7.7)
insight (b1644) 6 (5.8)
executive functions (b164) 5 (4.8)
language (b167) 3 (2.9)
Emotional functions 28 (26.9)
depression (b1522) 16 (15.4)
anxiety (b152) 14 (13.5)
anhedonia (b1520) 5 (4.8)
hostility (b1522) 5 (4.8)
flat affect (b1522) 4 (3.8)
dysphoria (b1522) 2 (1.9)
feelings of stress (b152) 2 (1.9)
in general (b152) 2 (1.9)
mania (b152) 2 (1.9)
anger (b152) 1 (1.0)
emotional regulation (b1521) 1 (1.0)
emotional withdrawal (b152) 1 (1.0)
Energy and drive 16 (15.4)
motivation (b1301) 7 (6.7)
libido (b1308) 4 (3.8)
appetite (b1302) 3 (2.9)
fatigue (b1300) 3 (2.9)
vitality (b1300) 3 (2.9)
apathy (b130) 2 (1.9)
Psychomotor functions (b147) 11 (10.6)
Sleep 10 (9.6)
insomnia (b1340) 8 (7.7)
somnolence (b1340) 7 (6.7)
Global psychosocial functions 9 (8.7)
emotional perception (b122) 6 (5.8)
social cognition (b122) 5 (4.8)
Sensory functions and pain
Pain (b280) 11 (10.6)
Activities and participation
Relationships with others 32 (30.8)
in general (d7) 19 (18.3)
family relationships (d760) 7 (6.7)
Table 1 Frequency of psychosocial difficulties (PSDs)
associated with schizophrenia identified in the literaturea
(Continued)











behaviour at work (d740) 1 (1.0)




in general (d850) 19 (18.3)
work efficiency (d850) 1 (1.0)
keeping employment (d8451) 1 (1.0)
obtaining employment (d845) 1 (1.0)
Looking after ones’ health 12 (11.5)
treatment adherence (d5702) 11 (10.6)









Communication (d3) 7 (6.7)
Doing housework (d640) 6 (5.8)
Leisure activites (d920) 5 (4.8)




negative symptoms 39 (37.5)
positive symptoms 39 (37.5)
global intensity of symptoms 37 (35.6)
general psychopathology 18 (17.3)
Disability and functioning 38 (36.5)
global disability or global
functioning
26 (25.0)
social functioning 18 (17.3)
Quality of life and wellbeing 24 (23.1)
quality of life 14 (13.5)
wellbeing 8 (7.7)
satisfaction in general 5 (4.8)
Health status 12 (11.5)
physical health 9 (8.7)
general health 6 (5.8)
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Table 1 Frequency of psychosocial difficulties (PSDs)
associated with schizophrenia identified in the literaturea
(Continued)
psychological health 5 (4.8)
mental health 3 (2.9)
Activities of daily living (ADL) 5 (4.8)
Other variables
Skills 11 (10.6)
social skills 8 (7.7)
general interpersonal skills 4 (3.8)
work skills 2 (1.9)
in general 2 (1.9)
communication skills 1 (1.0)
Attitude towards treatment 5 (4.8)
Dependency 5 (4.8)
in general 3 (2.9)





a Only PSD categories which appeared in at least 5 papers were taken into
account.
b Under the general category of psychopathological symptoms were classified
total scores of symptom rating scales, such as the PANSS or BPRS, or complex
symptom clusters (positive symptoms, negative symptoms, or general
psychopathology), which could not be linked to mental functions categories
included in the ICF. More specific symptom dimensions derived from the
PANSS or BPRS were placed under the respective categories of individual
mental functions (e.g. emotional functions or energy and drive functions).
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which were addressed in over a half (53%) of the
included papers, or disability and functioning, measured
in above a third (37%) of the papers. Other general
aspects of life related to PSDs, which appeared in the lit-
erature with a significant frequency, were quality of life
and wellbeing (23% of papers) and health status (12%).
Within the ICF domain of mental functions, the most
commonly assessed were cognitive functions (27%) and
emotional functions (27%), followed by energy and drive
(15%) and psychomotor functions (11%). Pain was also
reported in 11% of papers. As far as the ICF component
of activities and participation is concerned, the categor-
ies most widely investigated were relationships with
others (31%), employment (20%), and, to a lesser extent,
looking after one’s health (12%), participating in social
activities (11%), and self-care (11%). Furthermore, sev-
eral variables, which have not been comprehensively
classified in the ICF so far, appeared in at least five
papers, with various kinds of skills being the most fre-
quently studied (11%).Table 2 lists the outcome instruments used to assess
PSDs in at least 5 papers. The most widely used were
two symptom rating scales: PANSS (35% of papers) and
BPRS (14%).Variables associated with onset or course of PSDs
Variables associated with onset of PSDs were examined
rarely and were reported only in a small proportion of
papers (n = 17, 16.3%). Overall, seven categories of such
variables were found. The only one consistently identified
in the literature was medication, which was reported in
14 (13.5%) papers and found to contribute to the devel-
opment of 14 various PSDs (as adverse events): most fre-
quently pain (n = 11, 10.6%), anxiety (n = 8, 7.7%),
insomnia (n = 8, 7.7%), somnolence (n = 7, 6.7%),
increased appetite (n = 3, 2.9%), fatigue (n = 3, 2.9%), and
loss of libido (n = 3, 2.9%). Other factors associated with
onset of PSDs appeared in no more than two papers.
Factors related to the intensity or course of PSDs were
studied much more frequently – 105 categories of asso-
ciated variables were identified in 95 (91.3%) papers. The
variables found in more than 5 papers are presented in
Table 3 (included all variables which showed significant
associations with any of the PSDs investigated in a given
paper).
The most common were various forms of treatment
reported in over a half (56%) of the papers, followed by
psychopathological symptoms (26%), socio-demographic
variables (24%), global disability and functioning (13%),
emotional functions (12.5%), and cognitive functions
(12%).
Additional file 4: Table S2 shows how these variables
were associated with the 10 most relevant PSD categor-
ies (negative findings are not included).
Most frequently associated with positive outcomes in
psychosocial domains were various forms of treatment,
particularly medication and psychosocial interventions.
Psychopathological symptoms were most consistently
related to negative outcomes.Discussion
In this paper we reviewed recent research on PSDs
experienced by people with schizophrenia using a con-
sistent conceptual framework for understanding the dis-
ability experience: that embodied in the internationally
accepted standard of the ICF. Based on this conceptual
framework, we defined PSDs as impairments of mental
functions (including also pain and sexual interest func-
tions), activity limitations and participation restrictions.
So our approach was broader and more comprehensive
than adopted by those authors who tend to exclude dis-
turbances of mental functions (e.g. psychopathological
symptoms or cognitive deficits) from the definition of
Table 2 Outcome instruments most frequently used to assess PSDsa
Name of instrument Papers in which an instrument was used n (%)
Positive and Negative Syndrome Scale (PANSS) [20] 36 (34.6)
Brief Psychiatric Rating Scale (BPRS) [21] 15 (14.4)
Quality of Life Scale (QLS) [22] 7 (6.7)
Trail Making Test (TMT) [23] 7 (6.7)
Continuous Performance Test (CPT) [24] 6 (5.8)
Global Assessment of Functioning (GAF) [25] 6 (5.8)
Rey Auditory Verbal Learning Test (RAVLT) [26] 6 (5.8)
Scale for the Assessment of Negative Symptoms (SANS) [27] 6 (5.8)
Stroop Color and Word Test (SCWT) [28] 6 (5.8)
Subjective Well-Being Under Neuroleptic Treatment (SWN-K) [29] 6 (5.8)
World Health Organization Disability Assessment Schedule (WHODAS or WHODAS II) [30] 6 (5.8)
Clinical Global Impression-Schizophrenia scale (CGI-SCH) [31] 5 (4.8)
Montgomery-Åsberg Depression Scale (MADRS) [32] 5 (4.8)
Wechsler Adult Intelligence Scale (WAIS-R) [33] 5 (4.8)
Wechsler Memory Scale (WMS-R) [34] 5 (4.8)
Wisconsin Card Sorting Test (WCST) [35] 5 (4.8)
a Only instruments which were used in at least 5 studies were included.
Instruments were only taken into account if they were used for assessing dependent variables.
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sized as well, that unlike a large part of earlier
reviews targeting psychosocial problems of people with
schizophrenia, we excluded studies conducted on diag-
nostically heterogeneous samples, comprising people
with schizoaffective or other psychotic disorders. The
exclusive focus on people diagnosed with schizophrenia
is a strength of this paper, given the unclear nosological
status of schizoaffective disorder and a low reliability,
longitudinal stability and clinical utility of this diagnosis,
which is strongly recommended by prominent research-
ers in the field to be deleted from future revisions of the
classifications of mental disorders [1].
The analysis of the included papers resulted in identi-
fying more than a hundred PSD categories, which clearly
confirms that psychosocial problems encountered by
people with schizophrenia in their daily lives are very di-
verse. The most frequently addressed PSDs were related
to the areas of psychopathology, overall disability and
functioning, relationships with others, cognitive func-
tions, emotional functions, quality of life and wellbeing,
employment, and energy and drive. This pattern of find-
ings well reflects the core features of schizophrenia as a
disabling disease manifesting itself by an admixture of
positive, negative, cognitive, mood and motor symptoms,
variable degrees of functional, social and occupational
impairments, and marked worsening of both objective
and subjective indicators of quality of life [1].
Our analysis also revealed a wide variety of over a
hundred categories of factors associated with theintensity or course of PSDs. Of those, by far the most
commonly reported (in over 50% of the papers) were
treatment modalities, with medication being the most
frequent, followed by psychological and psychosocial
therapies. Therapeutic interventions generally had posi-
tive influence on PSDs, but only medication and to a
lesser extent psychosocial treatment were consistently
reported to positively affect a majority of the most rele-
vant PSDs, whereas the effects of other forms of therapy
were more selective. It should be borne in mind, though,
that the beneficial effects of medication came at a price,
because it was also found to be a determinant of onset
of quite a few PSDs.
The second most frequent group of factors associated
with PSDs were factors that are psychosocial problems
themselves, e.g. psychopathological symptoms, global
disability and functioning, emotional problems, or cogni-
tive deficits. It comes as no surprise that psychiatric
symptoms in particular were found to be associated with
negative outcomes in most of the main psychosocial
domains as they are a primary source of suffering and
life problems of schizophrenia patients. In more general
terms, our findings illustrate how various areas of psy-
chosocial functioning in schizophrenia are closely inter-
related and therefore cannot be targeted and effectively
ameliorated in isolation.
Socio-demographic variables emerged as the third par-
ticularly relevant group of variables related to the inten-
sity or course of PSDs. However, in this case the pattern
of relationships was much less clear, with working status
Table 3 Frequency with which variables associated with
intensity or course of PSDs were identified in the
literaturea
Associated variables Papers in which a
variable was identified
n (%)
Patient treatment 58 (55.8)
medication 32 (30.8)
psychosocial treatment 8 (7.7)
psychological therapy: cognitive therapy 7 (6.7)
alternative treatment 5 (4.8)
psychological therapy: cognitive behavioural
therapy
4 (3.8)
community-based care 1 (1.0)
day care 1 (1.0)
Psychopathological symptoms 27 (26.0)
positive symptoms 16 (15.4)
negative symptoms 14 (13.5)
global intensity of symptoms 10 (9.6)
general psychopathology 3 (2.9)
Demographics 25 (24.0)
employment status 14 (13.5)
gender 12 (11.5)
marital status 8 (7.7)
educational level 7 (6.7)
age 6 (5.8)
accommodation type 6 (5.8)
country of residence 3 (2.9)
urban or rural residence 3 (2.9)
social economic status 2 (1.9)
disability benefits 1 (1.0)
legal status 1 (1.0)
Disability and functioning 14 (13.5)
global disability or global functioning 9 (8.7)
social functioning 7 (6.7)
Emotional functions 13 (12.5)
depression 10 (9.6)
feelings of stress 3 (2.9)
anxiety 2 (1.9)
dysphoria 1 (1.0)
flat affect 1 (1.0)
hostility 1 (1.0)
Cognitive functions 12 (11.5)




executive functions 1 (1.0)
Table 3 Frequency with which variables associated with




Illness-related variables 10 (9.6)
age at first hospitalization 3 (2.9)
duration of illness 3 (2.9)
stage of illness 3 (2.9)
age at first treatment 2 (1.9)
age at illness onset 2 (1.9)
course of illness 2 (1.9)
duration of untreated psychosis 2 (1.9)
subtype of schizophrenia 2 (1.9)
age at discharge from hospital 1 (1.0)
Quality of life and wellbeing 9 (8.7)
quality of life 5 (4.8)
wellbeing 5 (4.8)
Social support 8 (7.7)
in general 6 (5.8)
family support 1 (1.0)
friend support 1 (1.0)
Comorbidities 7 (6.7)
substance abuse 4 (3.8)
physical comorbidity 3 (2.9)
Side-effects of medication 7 (6.7)
Treatment adherence 7 (6.7)
Relationships with others 6 (5.8)
in general 3 (2.9)
family relationships 2 (1.9)
aggressive behaviour 1 (1.0)
relationships with health professionals 1 (1.0)
Health services use 5 (4.8)
duration of hospitalizations 3 (2.9)
number of hospitalizations 2 (1.9)
duration of treatment 1 (1.0)
number of health professional visits 1 (1.0)
Psychomotor functions 5 (4.8)
Self-esteem 5 (4.8)
Support for caregivers 5 (4.8)
education 5 (4.8)
in general 1 (1.0)
mutual support 1 (1.0)
a Only associated variables which were identified in at least 5 papers were
taken into account.
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positive outcomes, and male gender most often being
related to negative outcomes. An earlier review on
schizophrenia and employment by Marwaha & Johnson
[13] showed the correlation of being employed with bet-
ter social functioning, quality of life and self-esteem, and
with lower symptom levels, but at the same time stressed
the scarcity of evidence for the causal relationships. Male
gender, in turn, is a well known predictor of poor out-
come of schizophrenia [3]. Overall, our review suggests
that socio-demographic characteristics play an important
role in shaping the daily experience of persons with
schizophrenia, but their interactions with psychosocial
outcomes are complex and difficult to synthesize. In the
framework of the ICF, socio-demographic characteristics
belong to the domain of contextual personal factors,
which until now has only preliminarily been outlined
[16]. A systematic exploration of the conceptualization
and operationalization of personal factors in the ICF
would help in studying them more rigorously and at the
same time provide a more complete understanding of the
experience of disability in persons with schizophrenia.
The present review points to several gaps and weak-
nesses in the literature. First of all, it should be noted
that the most widely studied were not specific PSDs in a
strict sense, directly linkable to the ICF categories of
mental functions, activity limitations or participation
restrictions, but rather broad areas of psychosocial func-
tioning, such as global severity of psychopathological
symptoms or complex symptom clusters (e.g. positive or
negative symptoms), overall disability and functioning.
Other general aspects of life that, with significant fre-
quency, were related to psychosocial functioning in
schizophrenia included quality of life, wellbeing and vari-
ous dimensions of health status. Although all these
broad constructs may be useful as outcome measures in
evaluating the effectiveness of therapeutic interventions,
they provide only limited information on psychosocial
problems actually experienced by people with schizo-
phrenia in real life. It is desirable that future research
should place more emphasis on specific areas of psycho-
social disability in schizophrenia which could be more
direct targets for interventions and policy changes.
Further, the relevant psychosocial areas that are under-
represented in the literature need to be mentioned. In
the light of the widely accepted view that the stigma
associated with schizophrenia is particularly high and
constitutes one of the main obstacles to social inclusion
and to better quality of life of people who have the ill-
ness [6], it is surprising that perception and experience
of stigma was a rarely investigated PSD in the reviewed
studies (below our threshold of 5 papers). Thus, al-
though recent decades witnessed a marked increase in
published research on psychiatric stigma [37], this trendwas not reflected in the present review. One explanation
may be that most studies examining stigma and discrim-
ination from the perspective of people with mental ill-
ness use cross-sectional designs and samples not
meeting our inclusion criteria regarding diagnosis [38].
However, the fact that in the included papers experience
of stigma was reported very infrequently not only as a
PSD, but also as a determinant of other PSDs (again,
below the set threshold of 5 articles) may indicate that it
is indeed still insufficiently taken into account in schizo-
phrenia research.
Another important schizophrenia-related PSD cat-
egory that seems to be understudied is that of tempera-
ment and personality functions, which were also
addressed in fewer than five articles. This is in contrast
with the results of two recent reviews focusing on the
disability of people with affective disorders (using the
ICF as a reference), in which temperament and personal-
ity functions were found to be among the most relevant
psychosocial factors [39,40]. It is even more surprising
that in the present review personality dimensions were
rarely (< 5 papers) identified as determinants of PSDs,
because there exists evidence for their substantial impact
on symptoms and various aspects of functioning in
people with psychotic disorders [41,42]. It appears, then,
that schizophrenia research concerning psychosocial
functioning is focused first and foremost on psychopath-
ology and functional outcomes, while personal disposi-
tions of people with schizophrenia is a largely neglected
and underestimated area.
We found that the most frequently used instruments
assessing PSDs were two symptom rating scales: PANSS
and BPRS. Although these scales have dominated the
field of schizophrenia research, their value as outcome
measures is rather limited and is increasingly ques-
tioned. It is argued that simply rating symptoms, without
careful evaluation of cognition, personal and social func-
tioning, is of little practical use [43]. Our review suggests
that schizophrenia research suffers from overreliance on
clinician-rated symptoms in the determination of out-
come. In the analyzed studies, all too often the outcome
measurement was based primarily on the global rating
of the severity of symptoms by means of the standar-
dized scales, with little attention being paid to a deeper
investigation of specific aspects of psychopathology and
to the assessment of other domains of psychosocial
functioning. It is also problematic that patient’s perspec-
tive on the psychic phenomena, which are a crucial as-
pect of their disease was largely overlooked. The self-
assessment symptom measures do not have a strong
tradition in schizophrenia research because of the objec-
tions to their validity, which contrasts with their popu-
larity in other mental disorders such as depression and
anxiety [44]. It seems, however, that, despite their
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turing the subjective experience of the patients and thus
in narrowing potential gap between clinicians’ and
patients’ perspectives. Besides assessments made by
trained professionals with regard to PSDs associated
with schizophrenia, future research needs to also focus
on individual importance attached to these PSDs such
that interventions can be appropriately prioritized.
The frequency of use of instruments assessing other
relevant psychosocial areas, such as cognition, depres-
sion, social functioning, disability or quality of life
demonstrates that no measure played a similarly prom-
inent role in the literature as the PANSS and BPRS in
the field of psychopathology assessment. This confirms
the conclusions of other researchers [36] that, so far,
there is no universally acknowledged gold standards in
these domains, which highlights the need for the devel-
opment of new outcome measures or better validation
of the existing ones.
Finally, it is worth noticing that in contrast to variables
associated with the intensity or course of PSDs, factors
related to the onset of PSDs were rarely reported in the
literature (with the notable exception of medication and
its side-effects). One main reason is probably the prac-
tical difficulty in designing studies that would be able to
capture the onset of PSDs and factors contributing to it.
A more extensive qualitative research on PSDs in schizo-
phrenia should be undertaken in order to hear directly
from the patients how their life problems started and
how they perceived their causes.
Our review should be interpreted in the light of several
limitations. First, we did not analyze papers published in
languages other than English. Thus, a possibility exists
that important findings from non-English speaking
countries were not taken into account. Second, only a
small proportion of the included studies came from
low- and middle-income countries. This restricts the
generalizability of the results, given that many psycho-
social problems in schizophrenia may be to a large ex-
tent dependent on economic, political and cultural
factors. Third, we only included longitudinal studies be-
cause these provide higher level of evidence, especially
in relation to the link between PSDs and associated vari-
ables. However, it is necessary to take into account when
interpreting the results of this review that cross-
sectional studies make up the lion’s share of schizophre-
nia research. Fourth, we only analyzed studies which
conceptualized PSDs as dependent variables and cannot
make inferences about which and how PSDs are used as
independent variables. Finally, our analysis of the rela-
tionships between the PSDs and other variables does not
allow for inferring causality. Because of the huge amount
and heterogeneity of analyzed variables, as well as the
great variability in study designs (including bothquantitative and qualitative research methods), types of
statistical analyses employed and the quality of reporting
the results, we decided to synthesize the data only at the
most basic level of associations.Conclusions
The present review illustrates the remarkably broad
scope and diversity of psychosocial areas affected in
schizophrenia. It shows how these areas are intercon-
nected and how they interact with contextual factors,
both environmental (e.g. treatments received) and per-
sonal ones (e.g. socio-demographic characteristics).
Therefore, it stresses the need for a comprehensive ap-
proach to schizophrenia-related PSDs in research and
clinical practice, since they can not be properly under-
stood and effectively improved in isolation and without
careful attention to the specific context in which they
appear.
Our findings point to the necessity of a shift in focus
of schizophrenia research from an excessive reliance on
global measures of psychopathology and disability in the
determination of outcome to a fuller consideration of
specific PSDs that have a more direct bearing on the
real-world functioning of the schizophrenia sufferers.
Researchers should also pay more attention to the inves-
tigation of perceptions and experiences of stigma, as well
as temperament and personality functions of people with
schizophrenia. A deeper exploration of these understud-
ied areas not only will shed more light on the extent of
psychosocial problems faced by the patients, but will
also be helpful in uncovering their personal strengths
that make them less vulnerable to disability and social
exclusion. As well, it would be advisable to put more
emphasis on the analysis of the determinants of onset of
PSDs.
Although up until now the application of the ICF in
psychiatry was rather limited [45], this review demon-
strates its usefulness in conceptualizing PSDs experienced
by schizophrenia patients. The further development of the
ICF (including an elaboration of personal factors) and its
wider implementation appears to be a promising means to
a more systematic and comprehensive investigation of
various dimensions of psychosocial disabilities in schizo-
phrenia along with their determinants. The ICF can also
serve as a basis for creating instruments comprehen-
sively assessing psychosocial outcomes in schizophrenia
that could be of use in both research and clinical
praxis. Understanding profiles of patients of schizophre-
nia at different stages of the illness and over time
would enable more effective matching of interventions,
such as skills training, and monitoring their impact over
time in terms of what really matters to patients and
caregivers.
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aFor the sake of simplicity, PSD categories were for-
mulated in neutral language (e.g. “cognitive functions”
instead of “impairments in cognitive functions”).
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